Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Depreciation & Amortization (2019 - 2025)

Atea Pharmaceuticals' Accumulated Depreciation & Amortization history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 37.65% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 37.65% year-over-year, with the annual reading at $1.5 million for FY2025, 37.65% up from the prior year.
  • Accumulated Depreciation & Amortization came in at $1.5 million for Q4 2025, up from $1.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.5 million in Q4 2025 to a low of $161000.0 in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $689000.0 (2023), against an average of $749800.0.
  • Year-over-year, Accumulated Depreciation & Amortization rose 21.97% in 2021 and then skyrocketed 152.38% in 2023.
  • Atea Pharmaceuticals' Accumulated Depreciation & Amortization stood at $161000.0 in 2021, then soared by 69.57% to $273000.0 in 2022, then surged by 152.38% to $689000.0 in 2023, then surged by 60.38% to $1.1 million in 2024, then surged by 37.65% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for AVIR's Accumulated Depreciation & Amortization are $1.5 million (Q4 2025), $1.1 million (Q4 2024), and $689000.0 (Q4 2023).